Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Strategies to overcome the main challenges of the use of CRISPR/Cas9 as a replacement for cancer therapy.

Molecular cancer - 3 Mar 2022

Rasul Mohammed Fatih, Hussen Bashdar Mahmud, Salihi Abbas, Ismael Bnar Saleh, Jalal Paywast Jamal, Zanichelli Anna, Jamali Elena, Baniahmad Aria, Ghafouri-Fard Soudeh, Basiri Abbas, Taheri Mohammad

Abstract excerpt

CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats-associated protein 9) shows the opportunity to treat a diverse array of untreated various genetic and complicated disorders. Therapeutic genome editing processes that target disease-causing genes or mutant genes have been greatly accelerated in recent years as a consequence of improvements in sequence-specific nuclease technology. However, the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CRISPR-Cas Systems
Share to Gene Editing

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Genetic Therapy

Share to Mutation

Share to Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 35241090
DOI: 10.1186/s12943-021-01487-4
PMCID: PMC8892709

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Strategies to overcome the main challenges of the use of CRISPR/Cas9 as a replacement for cancer therapy.PMID 35241090Read ↗

Genome Editing Approaches with CRISPR/Cas9 for Cancer Treatment: Critical Appraisal of Preclinical and Clinical Utility, Challenges, and Future ResearchSemantic proximity Read ↗

Clinical applications of the CRISPR/Cas9 genome-editing system: Delivery options and challenges in precision medicineSemantic proximity Read ↗

CRISPR/Cas9 in cancer: An attempt to the present trends and future prospects.Semantic proximity Read ↗

Prospects and challenges of CRISPR /Cas9 gene‐editing technology in cancer researchSemantic proximity Read ↗

CRISPR/Cas9 for cancer treatment: technology, clinical applications and challengesSemantic proximity Read ↗

Current Status of CRISPR/Cas9 Application in Clinical Cancer Research: Opportunities and ChallengesSemantic proximity Read ↗

CRISPR/Cas9-mediated genome editing: From basic research to translational medicine.Semantic proximity Read ↗

CRISPR/Cas9: an overview of recent developments and applications in cancer researchSemantic proximity Read ↗

CRISPR/Cas9 for Cancer Therapy: Hopes and ChallengesSemantic proximity Read ↗

CRISPR-Cas9 as a Potential Cancer Therapy Agent: An UpdateSemantic proximity Read ↗

Advances in therapeutic application of CRISPR-Cas9Semantic proximity Read ↗

Progress and Perspective of CRISPR‐Cas9 Technology in Translational MedicineSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.